Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole and Pantoprazole in Gastric Acid Hypersecretion
NCT00001191Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Feb 1983
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omeprazole and pantoprazole in Zollinger–Ellison syndrome (ZES) and gastric acid hypersecretion, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Control of symptoms due to high levels of gastric acid secretion and Gastric acid secretion levels. Started Feb 1983; status: completed.
02
Drugs
omeprazolepantoprazole
03
Conditions
Zollinger–Ellison syndrome (ZES)gastric acid hypersecretion
Beyond the preview
Go deeper on NCT00001191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001191.